Tissue Diagnostics Market Introduction and Overview
According to SPER Market Research, the Global Tissue Diagnostics Market is estimated to reach USD 20.08 billion by 2034 with a CAGR of 8.7%.
The report includes an in-depth analysis of the Global Tissue Diagnostics Market, including market size and trends, product mix, Applications, and supplier analysis. The Due to the rising prevalence of cancer, advancements in diagnostic technologies, and the growing demand for personalized medicine, the cancer market is expanding. The Pan American Health Organization (PAHO) predicts a significant increase in new cancer cases and cancer-related deaths in the coming years, with an ongoing rise in annual cases. Contributing factors include aging populations, the need for early disease detection, and innovations in immunohistochemistry and in situ hybridization techniques. Moreover, increased healthcare spending and global awareness of cancer screening programs are fueling the market's growth.
By Technology: The immunohistochemistry (IHC) segment is set to lead the market in 2024. IHC is a specialized staining technique where a diagnostic antibody binds to specific target proteins in tumor cells, visualized through a color reaction on tissue slides. It plays a crucial role in determining the appropriate drug therapy, aiding in early cancer diagnosis, prognosis assessment, and treatment prediction. IHC is essential in cancer research, diagnostics, and therapeutic development.
By Application: In 2024, the breast cancer segment is expected to lead the market, driven by rising incidence due to lifestyle changes and aging populations. It includes types like HR, HER2, and TNBC, with technologies like MarginProbe aiding cancer cell detection. Advancements in genomic testing also support growth. The non-small cell lung cancer (NSCLC) segment, comprising several subtypes, is also projected to grow significantly.
By Modality: The clinical market segment is expected to dominate in 2024, growing at the fastest rate due to advancements in medical technology, increasing disease prevalence, and the demand for personalized medicine. Innovations in tissue diagnostics, such as advanced imaging, molecular profiling, and AI integration, improve disease detection and patient outcomes. Meanwhile, the pharma/CRO/research segment is expanding rapidly, driven by the need for advanced diagnostics in drug discovery, development, and clinical trials.
By End User: Hospitals are expected to hold the largest revenue share in the market in 2024. The use of tissue diagnostic systems and services in hospitals and clinics has grown significantly over time. Many physicians are transitioning from traditional testing methods to tissue diagnostic tests due to the longer turnaround times of conventional procedures. These tests help shorten timelines, driving their increased adoption in medical settings.
By Regional Insights: The tissue diagnostics market in North America is expected to hold a significant share in 2024, driven by the growing demand for advanced diagnostic tools amid the rising prevalence of cancer and other diseases. The need for accurate, early diagnosis is expected to spur innovation in technologies like digital pathology and biomarker analysis. Additionally, the region's strong healthcare infrastructure and substantial investments in research and development are further fueling market growth.
Market Competitive Landscape:
The market is moderately consolidated. Some of the market key players are Abbott Laboratories, Agilent Technologies, BD, Bio SB, BioGenex, bioMérieux SA, Cell Signaling Technology, Inc., Danaher, DiaGenic ASA, F. Hoffmann-La Roche Ltd., GE Healthcare, Merck KGaA, QIAGEN, and Others.
Recent Developments:
- In January 2024, QIAGEN opened a new regional headquarters in Dubai, United Arab Emirates, as part of its Middle East expansion. In addition to improving access to the company's molecular diagnostics and sample preparation technology, this strategic step supports the company's objective of expanding its footprint in emerging markets. In order to further QIAGEN's objective of expanding its presence in the area and cultivating regional alliances, the new headquarters will assist important initiatives in the fields of healthcare, research, and industry.
- Merck KGaA opened a new $21.88 million distribution center in Cajamar, Sao Paulo, Brazil, in February 2024 with the goal of better serving its life science customers. This investment supports the region's delivery of cutting-edge tissue diagnostics solutions by improving Merck's operational responsiveness and efficiency.
Scope of the Report:
| Report Metric | Details |
| Market size available for years | 2021-2034 |
| Base year considered | 2024 |
| Forecast period | 2025-2034 |
| Segments covered | By Technology, By Application, By Modality, By End Use. |
| Regions covered | North America, Latin America, Asia-Pacific, Europe, and Middle East & Africa. |
| Companies Covered | Abbott Laboratories, Agilent Technologies, BD, Bio SB, BioGenex, bioMerieux SA, Cell Signaling Technology, Inc., Danaher, DiaGenic ASA, F. Hoffmann-La Roche Ltd., GE Healthcare, Merck KGaA, QIAGEN, and Others. |
Key Topics Covered in the Report:
- Global Tissue Diagnostics Market Size (FY’2021-FY’2034)
- Overview of Global Tissue Diagnostics Market
- Segmentation of Global Tissue Diagnostics Market By Technology (Immunohistochemistry, In Situ Hybridization, Primary & Special Staining, Digital Pathology and Workflow, Anatomic Pathology, Molecular Pathology)
- Segmentation of Global Tissue Diagnostics Market By Application (Breast Cancer, Non-small Cell Lung Cancer, Prostate Cancer, Gastric Cancer, Other Cancers)
- Segmentation of Global Tissue Diagnostics Market By Modality (Clinical, Pharma / CRO / Research Market)
- Segmentation of Global Tissue Diagnostics Market By End Use {(Hospitals, Diagnostic Center, Pharmaceutical Organizations, Contract Research Organizations (CROs)}
- Statistical Snap of Global Tissue Diagnostics Market
- Expansion Analysis of Global Tissue Diagnostics Market
- Problems and Obstacles in Global Tissue Diagnostics Market
- Competitive Landscape in the Global Tissue Diagnostics Market
- Details on Current Investment in Global Tissue Diagnostics Market
- Competitive Analysis of Global Tissue Diagnostics Market
- Prominent Players in the Global Tissue Diagnostics Market
- SWOT Analysis of Global Tissue Diagnostics Market
- Global Tissue Diagnostics Market Future Outlook and Projections (FY’2025-FY’2034)
- Recommendations from Analyst
1. Introduction
1.1. Scope of the report
1.2. Market segment analysis
2. Research Methodology
2.1. Research data source
2.1.1. Secondary Data
2.1.2. Primary Data
2.1.3. SPERs internal database
2.1.4. Premium insight from KOLs
2.2. Market size estimation
2.2.1. Top-down and Bottom-up approach
2.3. Data triangulation
3. Executive Summary
4. Market Dynamics
4.1. Driver, Restraint, Opportunity and Challenges analysis
4.1.1. Drivers
4.1.2. Restraints
4.1.3. Opportunities
4.1.4. Challenges
5. Market variable and outlook
5.1. SWOT Analysis
5.1.1. Strengths
5.1.2. Weaknesses
5.1.3. Opportunities
5.1.4. Threats
5.2. PESTEL Analysis
5.2.1. Political Landscape
5.2.2. Economic Landscape
5.2.3. Social Landscape
5.2.4. Technological Landscape
5.2.5. Environmental Landscape
5.2.6. Legal Landscape
5.3. PORTERs Five Forces
5.3.1. Bargaining power of suppliers
5.3.2. Bargaining power of buyers
5.3.3. Threat of Substitute
5.3.4. Threat of new entrant
5.3.5. Competitive rivalry
5.4. Heat Map Analysis
6. Competitive Landscape
6.1. Global Tissue Diagnostics Market Manufacturing Base Distribution, Sales Area, Product Type
6.2. Mergers & Acquisitions, Partnerships, Product Launch, and Collaboration in Global Tissue Diagnostics Market
7. Global Tissue Diagnostics Market, By Technology, (USD Million) 2021-2034
7.1. Immunohistochemistry
7.2. In Situ Hybridization
7.3. Primary & Special Staining
7.4. Digital Pathology and Workflow
7.5. Anatomic Pathology
7.6. Molecular Pathology
8. Global Tissue Diagnostics Market, By Application, (USD Million) 2021-2034
8.1. Breast Cancer
8.2. Non-small Cell Lung Cancer
8.3. Prostate Cancer
8.4. Gastric Cancer
8.5. Other Cancers
9. Global Tissue Diagnostics Market, By Modality, (USD Million) 2021-2034
9.1. Clinical
9.2. Pharma / CRO / Research Market
10. Global Tissue Diagnostics Market, By End Use, (USD Million) 2021-2034
10.1. Hospitals
10.2. Diagnostic Center
10.3. Pharmaceutical Organizations
10.4. Contract Research Organizations (CROs)
11. Global Tissue Diagnostics Market, (USD Million) 2021-2034
11.1. Global Tissue Diagnostics Market Size and Market Share
12. Global Tissue Diagnostics Market, By Region, (USD Million) 2021-2034
12.1. Asia-Pacific
12.1.1. Australia
12.1.2. China
12.1.3. India
12.1.4. Japan
12.1.5. South Korea
12.1.6. Rest of Asia-Pacific
12.2. Europe
12.2.1. France
12.2.2. Germany
12.2.3. Italy
12.2.4. Spain
12.2.5. United Kingdom
12.2.6. Rest of Europe
12.3. Middle East and Africa
12.3.1. Kingdom of Saudi Arabia
12.3.2. United Arab Emirates
12.3.3. Qatar
12.3.4. South Africa
12.3.5. Egypt
12.3.6. Morocco
12.3.7. Nigeria
12.3.8. Rest of Middle-East and Africa
12.4. North America
12.4.1. Canada
12.4.2. Mexico
12.4.3. United States
12.5. Latin America
12.5.1. Argentina
12.5.2. Brazil
12.5.3. Rest of Latin America
13. Company Profile
13.1. Abbott Laboratories
13.1.1. Company details
13.1.2. Financial outlook
13.1.3. Product summary
13.1.4. Recent developments
13.2. Agilent Technologies
13.2.1. Company details
13.2.2. Financial outlook
13.2.3. Product summary
13.2.4. Recent developments
13.3. BD
13.3.1. Company details
13.3.2. Financial outlook
13.3.3. Product summary
13.3.4. Recent developments
13.4. Bio SB
13.4.1. Company details
13.4.2. Financial outlook
13.4.3. Product summary
13.4.4. Recent developments
13.5. BioGenex
13.5.1. Company details
13.5.2. Financial outlook
13.5.3. Product summary
13.5.4. Recent developments
13.6. bioMerieux SA
13.6.1. Company details
13.6.2. Financial outlook
13.6.3. Product summary
13.6.4. Recent developments
13.7. Cell Signaling Technology, Inc.
13.7.1. Company details
13.7.2. Financial outlook
13.7.3. Product summary
13.7.4. Recent developments
13.8. Danaher
13.8.1. Company details
13.8.2. Financial outlook
13.8.3. Product summary
13.8.4. Recent developments
13.9. DiaGenic ASA
13.9.1. Company details
13.9.2. Financial outlook
13.9.3. Product summary
13.9.4. Recent developments
13.10. F. Hoffmann-La Roche Ltd.
13.10.1. Company details
13.10.2. Financial outlook
13.10.3. Product summary
13.10.4. Recent developments
13.11. GE Healthcare
13.11.1. Company details
13.11.2. Financial outlook
13.11.3. Product summary
13.11.4. Recent developments
13.12. Merck KGaA
13.12.1. Company details
13.12.2. Financial outlook
13.12.3. Product summary
13.12.4. Recent developments
13.13. QIAGEN
13.13.1. Company details
13.13.2. Financial outlook
13.13.3. Product summary
13.13.4. Recent developments
13.14. Others
14. Conclusion
15. List of Abbreviations
16. Reference Links